CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM
Executive Summary
Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study
You may also be interested in...
CER Credibility Lies In Methodology For Studies, Physician Tells BIO
The credibility of comparative effectiveness research ultimately will be judged based on the methodology used to conduct the research, David Charles, associate professor and vice-chairman of neurology at Vanderbilt University Medical Center and chairman of the physician group Alliance for Patient Access, told attendees during a session at the Biotechnology Industry Organization International Convention.
CER Credibility Lies In Methodology For Studies, Physician Tells BIO
The credibility of comparative effectiveness research ultimately will be judged based on the methodology used to conduct the research, David Charles, associate professor and vice-chairman of neurology at Vanderbilt University Medical Center and chairman of the physician group Alliance for Patient Access, told attendees during a session at the Biotechnology Industry Organization International Convention.
FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning
The review of Vanda’s Fanapt casts into relief the contours of FDA’s authority to consider comparative efficacy as a factor in drug approval decisions.